Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05798663 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
A Phase 2 study of NSCLC, sponsored by Alliance Foundation Trials.
- Active
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 15
- Study locations
NCT05798663 is a Phase 2 study of NSCLC that is active but no longer recruiting, run by Alliance Foundation Trials. The registered enrollment target is 178 participants, below the 221-participant average among 71 other NSCLC trials with a reported enrollment target (19% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT05798663, a Phase 2 study of NSCLC, is active but no longer recruiting, sponsored by Alliance Foundation Trials.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tiragolumab
Study Locations (15)
California
- University of California San Diego Moores Cancer Center - La Jolla
- Kaiser Permanente Oakland Medical Center - Oakland
- Kaiser Permanente Roseville Medical Center - Roseville
- Kaiser Permanente San Francisco Medical Center - San Francisco
- Kaiser Permanente Santa Clara Medical Center - Santa Clara
- Kaiser Permanente Vallejo Medical Center - Vallejo
Missouri
- Washington University Siteman Cancer Center - St Louis
- Missouri Baptist Medical Center - St Louis
New York
- Hematology Oncology Associates of Central New York, P.C. - East Syracuse
- SUNY Upstate Medical University - Syracuse
Illinois
- Rush University Medical Center - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
New Hampshire
- New Hampshire Oncology - Hematology, PA - Manchester
Ohio
- Ohio State University - Columbus
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05798663
The ClinicalTrials.gov registry entry for NCT05798663 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 71 other NSCLC trials with a reported enrollment target (19% lower). The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05798663 reports 15 study locations spanning 8 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT05798663 about?
NCT05798663 is a clinical study titled "Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC". This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
What is the current status of trial NCT05798663?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2023-12-07. Estimated completion is 2026-11.
What conditions does trial NCT05798663 study?
This clinical trial studies the following conditions: NSCLC.
What interventions are being tested in trial NCT05798663?
The interventions under investigation include: Atezolizumab (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT05798663?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05798663 being conducted?
This trial has 15 study locations across California, Illinois, Missouri, Nebraska, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.